← Back to Search

Antioxidant

MitoQ for Lower Urinary Tract Symptoms (Mito-LUTS Trial)

Phase 2
Recruiting
Led By Iman M Al-Naggar, PhD
Research Sponsored by Iman Al-Naggar, PhD
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up week 0, week 4, week 8, week 12, week 16
Awards & highlights

Summary

This trial aims to see if a supplement called MitoQ can help improve bladder symptoms in women aged 50-75 with metabolic syndrome. Participants will take the supplement daily for 4 months and undergo

Who is the study for?
This trial is for women aged 50-75 with metabolic syndrome who experience bladder issues like urgency and frequency. Participants must be willing to take capsules, answer health questions, undergo tests, provide samples, keep a bladder diary, and attend visits and calls over 4 months.Check my eligibility
What is being tested?
Researchers are testing MitoQ supplements against a placebo to see if they improve bladder symptoms in older women with metabolic syndrome. The study involves taking two capsules daily for four months and monitoring the effects on urinary tract symptoms.See study design
What are the potential side effects?
The description does not specify side effects of MitoQ; however, as with any supplement or medication, there could be potential risks which will be monitored throughout the study.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~week 0, week 4, week 8, week 12, week 16
This trial's timeline: 3 weeks for screening, Varies for treatment, and week 0, week 4, week 8, week 12, week 16 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Overactive Bladder Symptom Score (OABSS)
Secondary outcome measures
Three-day bladder voiding diary

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: MitoQ groupExperimental Treatment1 Intervention
2x20mg MitoQ (mitoquinol mesylate) capsules taken orally daily before breakfast for 4 months
Group II: Placebo Control groupPlacebo Group1 Intervention
2 placebo capsules taken orally daily before breakfast for 4 months

Find a Location

Who is running the clinical trial?

National Institute on Aging (NIA)NIH
1,704 Previous Clinical Trials
28,033,207 Total Patients Enrolled
Iman Al-Naggar, PhDLead Sponsor
American Urological AssociationOTHER
4 Previous Clinical Trials
585 Total Patients Enrolled
~33 spots leftby Dec 2025